Market for Cancer Therapies Could Reach $7 Billion

According to a new report recently released by Medical Data International (Irvine, CA) titled, "U.S. Markets for Cancer Therapeutic and Management Products," the cumulative market for cancer therapies and support products is expected to approach $7 billion by 2002.

The 293-page report provides detailed analyses, market statistics and growth projections for the products, trends and technologies in cancer therapy. The report was written to provide business executives at medical device, diagnostic and pharmaceutical companies with the tools for making strategic planning decisions in the cancer therapeutics marketplace.

Key market participants profiled, include: Abbott Laboratories; Amgen, Inc.; Baxter International, Inc.; Bristol-Myers Squibb Company; CellPro, Inc.; Elekta Instruments, Inc.; Genentech, Inc.; Glaxo Wellcome, Inc.; Novartis; Nucletron; Pharmacia & Upjohn, Inc.; Quadra Logic Technologies, Inc.; Rhone- Poulenc Rorer, Inc.; Schering-Plough Corporation; Siemens Medical Systems, Inc.; Theragenics Corporation; Theratronics International, Ltd.; Tyco International, Ltd.; Varian Associates, Inc.; Zeneca PLC.

Medical Data International, an IHS Group Company, is a business knowledge company serving the medical technology and managed care segments of the worldwide healthcare industry

For more information: Abida Baig, Medical Data International. Tel: 800-826-5759, or 949-955-6306.